News
Academy
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Latest Executive Roundtables
  • Asembia 2025
  • Sales Effectiveness
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Article

January 30, 2018

CRO Trends 2018

Author(s):

Nuala Murphy

Improving the productivity of sponsors’ clinical development processes will continue to be a primary driver of outsourcing in 2018, writes Nuala Murphy.

Improving the productivity of sponsors’ clinical development processes will continue to be a primary driver of outsourcing in 2018 and beyond. Sponsors will persist in their drive for new ways to help them improve cycle times and reduce costs. We expect this will increase interest in specialist capabilities such as risk based monitoring, adaptive trial designs and flexible delivery models.

Sponsors will also be looking to leverage the investments that CROs have made in new capabilities that address key development challenges such as big data partnerships to improve site identification, patient recruitment, health economics and outcomes research.

We expect there will also be demand for services in the areas of orphan and rare disease drug development as sponsors look for specialist therapeutic knowledge and global site relationships to help them design smarter trials and recruit patients faster in these complex areas.

Sponsors need to increasingly generate outcomes data both as part of the product approval submission and as part of post-approval research programs. This requirement to be able to demonstrate the economic value of new treatments will present a growth opportunity for CROs who can offer support in developing and interpreting outcomes data. There will also be the expectation that CROs can keep up to date with evolving regulatory requirements and collaborate with organisations such as International Consortium for Health Outcomes Measurement (ICHOM), that are setting the standards in benchmarking and systems for data collation.

Patient access: recruitment & engagement

Improving patients’ lives will always be the priority in drug development. In clinical trials, this means everything from defining outcomes that make the most difference in patient’s lives, making trials more accessible to patients who are identified through EMRs in their physicians’ office, to minimizing control arms using advanced statistical methods and providing study results as soon as they are available.

Patient recruitment persists as the key driver of cost in clinical development and will remain a focus for the years to come. Industry sources estimate that it can account for over 30% of a trials budget, but it is still often the delay factor in studies. According to Tufts 11% of sites fail to recruit a single patient and over 37% underperform in recruitment target.

CROs will continue to look for new ways to approach this challenge, whether that is decreasing the burden on patients to make clinical trials a care option, putting site networks in place to make the process and outcomes more predictable, supporting sites more fully in the training and tools they need or the automated data collection and analytics of electronic medical records (EMR). 

Applied innovation  

Innovation is playing an increasingly important role in helping to support more efficient drug development. Sponsors and CROs are engaging in discussions in how new approaches coupled with existing, tested technologies and sophisticated analytics can substantially reduce the risk and cost of clinical drug development.  It will be important that CROs are able to streamline these solutions and reduce the number of systems involved to deliver a standardized environment on a unified, centralized platform.

CROs will continue to collaborate with sponsors in the deployment of cutting edge technology for example the emerging role of wearables and sensors in clinical trials, which sponsors can adopt to drive additional value in their development programs.

Adaptive design is no longer a new, unproven concept. However, each adaptive trial provides insight on how to best design and execute the next study. The lessons, and responses to them, will enable CROs to consistently and efficiently design and execute effective, complex adaptive clinical trials. The next step will be to create scientific machinery that further saves resources, optimises development, and enhances knowledge about the effects of drugs and devices.  

ICON is partnering to lead this effort and is applying quantum computing to machine learning models to predict clinical trial outcomes. Such initiatives will redefine how sponsors use data and adaptive design to accelerate development opening the way to more widespread adoption.  We estimate that optimal use of adaptive trials across a portfolio, which is encouraged by regulatory agencies in Europe and the US, could reduce trial costs, by 25 percent.

Nuala Murphy is President, Clinical Research Services, ICON Plc.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Gen Li
Gen Li
Related Content
Advertisement
Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment
August 2nd 2025

Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment

Don Tracy, Associate Editor
Gene Mack, CEO, GAIN Therapeutics, shares how growing clinician confidence and strong early experiences helped accelerate enrollment in the company’s Phase Ib Parkinson’s disease trial.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 2nd 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Exploring the Promise of E7386 and Lenvatinib Combination Therapy in Endometrial Carcinoma
August 2nd 2025

Exploring the Promise of E7386 and Lenvatinib Combination Therapy in Endometrial Carcinoma

Don Tracy, Associate Editor
Corina Dutcus, SVP, oncology global clinical development lead at Eisai, discusses the potential of the E7386 and lenvatinib combination to address unmet needs in second-line treatment for endometrial carcinoma patients.
Key Findings of the NIAGARA and HIMALAYA Trials
August 2nd 2025

Key Findings of the NIAGARA and HIMALAYA Trials

Don Tracy, Associate Editor
In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir in HIV
August 2nd 2025

FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir in HIV

Don Tracy, Associate Editor
The new drug application is supported by 48-week data from the Phase III MK-8591A-051 and MK-8591A-052 trials, which showed that the doravirine/islatravir combination was non-inferior to both baseline antiretroviral therapy and to bictegravir/emtricitabine/tenofovir alafenamide in treating HIV.
How Unified Platforms are Reshaping Clinical Trial Economics
August 2nd 2025

How Unified Platforms are Reshaping Clinical Trial Economics

Chris Driver
The traditional approach to trial management relies on a mix of solutions that often become siloed and difficult to integrate.
Related Content
Advertisement
Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment
August 2nd 2025

Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment

Don Tracy, Associate Editor
Gene Mack, CEO, GAIN Therapeutics, shares how growing clinician confidence and strong early experiences helped accelerate enrollment in the company’s Phase Ib Parkinson’s disease trial.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 2nd 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Exploring the Promise of E7386 and Lenvatinib Combination Therapy in Endometrial Carcinoma
August 2nd 2025

Exploring the Promise of E7386 and Lenvatinib Combination Therapy in Endometrial Carcinoma

Don Tracy, Associate Editor
Corina Dutcus, SVP, oncology global clinical development lead at Eisai, discusses the potential of the E7386 and lenvatinib combination to address unmet needs in second-line treatment for endometrial carcinoma patients.
Key Findings of the NIAGARA and HIMALAYA Trials
August 2nd 2025

Key Findings of the NIAGARA and HIMALAYA Trials

Don Tracy, Associate Editor
In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir in HIV
August 2nd 2025

FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir in HIV

Don Tracy, Associate Editor
The new drug application is supported by 48-week data from the Phase III MK-8591A-051 and MK-8591A-052 trials, which showed that the doravirine/islatravir combination was non-inferior to both baseline antiretroviral therapy and to bictegravir/emtricitabine/tenofovir alafenamide in treating HIV.
How Unified Platforms are Reshaping Clinical Trial Economics
August 2nd 2025

How Unified Platforms are Reshaping Clinical Trial Economics

Chris Driver
The traditional approach to trial management relies on a mix of solutions that often become siloed and difficult to integrate.
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.